STOCK TITAN
  1. Home
  2. Sec-filings
  3. INDP
  4. [8-K] Indaptus Therapeutics, Inc. Reports Material Event

Indaptus Therapeutics (INDP) names new CFO and independent director

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. reported leadership and board changes. Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and the company stated his resignation was not due to any disagreement regarding operations, policies, or practices.

On March 31, 2026, the board appointed Qinglai Lu, 48, as a director effective April 8, 2026 and determined he qualifies as an independent director under Nasdaq rules. The board also appointed Yu Ding, 51, as Chief Financial Officer effective April 1, 2026 after reviewing his qualifications.

The company adjusted its audit committee, with Matthew McMurdo resigning and Qinglai Lu and Jerome Jabbour joining the committee on March 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
CFO resignation effective date April 1, 2026 Effective date of Nir Sassi’s resignation as Chief Financial Officer
New director effective date April 8, 2026 Date when Qinglai Lu joins the Board of Directors
New CFO appointment date April 1, 2026 Effective date of Yu Ding’s appointment as Chief Financial Officer
Age of new director 48 years Age of newly appointed director Qinglai Lu
Age of new CFO 51 years Age of newly appointed Chief Financial Officer Yu Ding
Audit committee changes date March 31, 2026 Date of audit committee resignation and new appointments
Chief Financial Officer financial
"Nir Sassi resigned as Chief Financial Officer on April 1, 2026."
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
independent regulatory
"The Board of Directors of the Company deemed Qinglai Lu to qualify as “independent” in accordance with the listing requirements of Nasdaq."
Audit Committee financial
"On March 31, 2026, Matthew McMurdo resigned as a member of the Audit Committee, and Qinglai Lu and Jerome Jabbour were appointed to the Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Monetary Authority of Singapore regulatory
"CPI Capital Management (Singapore) received regulatory approval from the Monetary Authority of Singapore to conduct fund management business in April 2025"
The Monetary Authority of Singapore is the main organization responsible for overseeing the country's money supply, banking system, and financial stability. It acts like a central bank, setting rules to keep the financial system safe and healthy. For investors, it matters because its policies influence interest rates, inflation, and the overall economic environment, impacting investment opportunities and risks.
Nasdaq Capital Market market
"Common Stock, $0.01 par value | | INDP | | Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Understanding 8-K Material Events →
false 0001857044 0001857044 2026-03-31 2026-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 31, 2026

 

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40652   86-3158720

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3 Columbus Circle 15th Floor

New York, New York

   10019
(Address of principal executive offices)   (Zip Code)

 

(646) 427-2727

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.01 par value   INDP   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Officer

 

Nir Sassi resigned as Chief Financial Officer on April 1, 2026. Mr. Sassi’s resignation is not based on any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

 

Appointment of Director and Officer

 

On March 31, 2026, the Board of Directors appointed Qinglai Lu as a member of the Board of Directors, effective April 8, 2026. The Board of Directors of the Company deemed Qinglai Lu to qualify as “independent” in accordance with the listing requirements of Nasdaq.

 

Qinglai Lu, 48, brings over 20 years of experience across corporate finance, banking and debt capital markets, asset management, distressed investments, and private banking in the Asia-Pacific region. Mr. Lu joined Plunkett Capital in May 2019 as Managing Partner. His key responsibilities included structuring and arranging private credit and equity financing for corporates, while deploying proprietary capital and managed funds to invest alongside such transactions; leading the firm’s proprietary investment in a regional multi-family office and serving on its board, participating in strategic decision-making and major initiatives, while building deep relationships with dozens of entrepreneurial families across Asia-Pacific; developing asset management and direct investment opportunities across Asia-Pacific, with a strategic focus on Japan and Singapore. Under Mr. Lu’s leadership as CEO, CPI Capital Management (Singapore) received regulatory approval from the Monetary Authority of Singapore to conduct fund management business in April 2025; and spearheading investments and asset management initiatives in virtual assets and Web3, including RWA tokenization of traditional financial assets and providing asset management solutions for stablecoin issuers. Prior to joining Plunkett Capital, Mr. Lu served as Head of Financing Solutions, Private Banking Asia at Goldman Sachs (Asia) LLC from 2018 to 2019.

 

Mr. Lu graduated from Shanghai Jiao Tong University in 1999 with a Bachelor’s degree in Communications Engineering and has been a Chartered Financial Analyst (CFA) charterholder since 2005.

 

On April 1, 2026, the Board of Directors appointed Yu Ding as Chief Financial Officer of the Company, effective immediately, after a thorough review of Yu Ding’s qualifications.

 

Yu Ding, 51, is a financial executive with over 20 years of extensive experience across commercial and financial markets. He has worked in capital management, strategic financial planning, and cross-sectoral leadership. Yu Ding has experience navigating complex regulatory environments for publicly traded companies on the Shanghai and Hong Kong Stock Exchanges. He was the Vice President and Chief Financial Officer of Grand Auto Service Group Co., Ltd. (600297.SS) in Shanghai, China from August 2023 to January 2026. Yu Ding also served as Chief Financial Officer for the Hong Kong Stock Exchange-listed entity, Grand Baoxin Auto Group Limited during such time. From May 2019 to December 2019, he was the Vice President of China ZhengTong Auto Services Holdings Limited (1728.HK) in Hong Kong.

 

Yu Ding graduated from the University of Canberra, Australia with a Master of Business Administration (MBA) in November 2006 and from East China Normal University with a China Bachelor’s Degree in International Accounting in July 1995.

 

Committee Appointments

 

On March 31, 2026, Matthew McMurdo resigned as a member of the Audit Committee, and Qinglai Lu and Jerome Jabbour were appointed to the Audit Committee by the Board of Directors.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

   Description
104   Cover Page Interactive Data File

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 3, 2026

 

  INDAPTUS THERAPEUTICS, INC.
     
  By: /s/ Junyi Dai
  Name: Junyi Dai
  Title: Chief Executive Officer

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What leadership changes did Indaptus Therapeutics (INDP) announce in this 8-K?

Indaptus Therapeutics announced that Chief Financial Officer Nir Sassi resigned effective April 1, 2026. The board simultaneously appointed Yu Ding as the new Chief Financial Officer and Qinglai Lu as a new independent director, alongside changes to the audit committee.

Why did Indaptus Therapeutics CFO Nir Sassi resign?

The company stated that Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and that his resignation was not based on any disagreement with Indaptus on matters relating to operations, policies, or practices, suggesting an orderly leadership transition.

Who is the new Chief Financial Officer of Indaptus Therapeutics (INDP)?

Yu Ding, 51, was appointed Chief Financial Officer effective April 1, 2026. He has over 20 years of experience in capital management and strategic financial planning, including CFO roles at Grand Auto Service Group Co., Ltd. and Grand Baoxin Auto Group Limited in China and Hong Kong.

What is the background of new Indaptus director Qinglai Lu?

Qinglai Lu, 48, has more than 20 years of experience in corporate finance, banking, asset management, and distressed investments across Asia-Pacific. He is Managing Partner at Plunkett Capital and previously led financing solutions for Private Banking Asia at Goldman Sachs (Asia) LLC.

How did Indaptus Therapeutics change its audit committee in this filing?

On March 31, 2026, Matthew McMurdo resigned from the Audit Committee. The board appointed Qinglai Lu and Jerome Jabbour to the Audit Committee, updating its composition while keeping overall board oversight of financial reporting and controls in place.

Is new director Qinglai Lu considered independent under Nasdaq rules for INDP?

Yes. The board of Indaptus Therapeutics determined that Qinglai Lu qualifies as an independent director under the listing requirements of Nasdaq. This classification is important for meeting exchange governance standards related to board and committee composition.

Filing Exhibits & Attachments

3 documents

Other Documents